Patricia Inácio, PhD,  science writer—

Anumana‘s artificial intelligence (AI) algorithm shows promise for the early detection of pulmonary hypertension (PH), a study suggested. The PH Early Detection Algorithm, which analyzes data collected from a routine electrocardiogram (ECG) heart test, was developed by scientists at Anumana, Janssen Research and Development, the Mayo Clinic,…

A new study identifies the presence of bacteria from the genus Eubacterium fissicatena, known for their pro-inflammatory properties, as a risk factor for pulmonary arterial hypertension (PAH). While the findings suggest “specific intestinal bacteria” are biomarkers for pulmonary PAH, and show “compelling evidence” that connects gut imbalance, or dysbiosis,…

The physical activity component of the PAH-SYMPACT — a patient-reported measure of quality of life tailored for people with pulmonary arterial hypertension (PAH) — is an independent predictor of the risk of death among PAH patients, according to a new study from Australia. One unit increase in this parameter…

Direct oral anticoagulants (DOACs) — a type of blood thinner medication — are as safe and effective as vitamin K antagonists (VKAs), the standard blood thinner used to treat chronic thromboembolic pulmonary hypertension (CTEPH), according to a meta-analysis of published studies. The findings support the use of DOACs as a…

Life support measures, specifically the need for assisted breathing, and elevated blood levels of bilirubin, a marker of liver damage, are among the factors that predict worse outcomes after a lung transplant in people with idiopathic pulmonary arterial hypertension (IPAH), a study reports. A new predictive model that includes…

Tenax Therapeutics has been granted another U.S. patent for levosimendan, this one covering all three routes of administration and its active metabolites, for the treatment of people with PH-HFpEF, or pulmonary hypertension and heart failure with preserved ejection fraction. Issued by the U.S. Patent and Trademark Office, the…

Elevated levels of two tumor biomarkers, AFP and CA125, were found to predict disease worsening in people with idiopathic pulmonary arterial hypertension (IPAH) in a new study from China. “Changes in AFP over time serve as an indicator of disease alteration, enabling detection of disease progression or treatment response,”…

About 41% of pulmonary arterial hypertension (PAH) patients in a multinational survey were initially misdiagnosed, seeing an average of 2.9 physicians before getting their correct diagnosis. The non-specific nature of their disease symptoms and a lack of awareness among patients and primary care physicians contribute to this delay,…

An algorithm based on artificial intelligence (AI) and machine learning may help in diagnosing pulmonary hypertension (PH), a new study shows. Its findings are particularly important for people suspected of having PH but whose disease remains uncertain using echocardiography, a noninvasive imaging method to examine heart structure and function.

Aria CV’s second-generation medical device for treating people with pulmonary arterial hypertension (PAH) — a balloon system known as the Gen 2 — has been successfully implanted in the first patient taking part in a U.S. study, according to a company press release. The…

A research project to help shed light about why people with the human immunodeficiency virus (HIV) are at higher risk for developing pulmonary hypertension (PH) was awarded a $2.67 million grant. The four-year grant from the National Heart, Lung and Blood Institute, part of the…

Sensydia announced that it successfully completed a fifth study of its investigative Cardiac Performance System (CPS), intended to more easily and quickly detect pulmonary hypertension (PH) and heart failure than current approaches. CPS is a handheld and noninvasive device, powered by artificial intelligence, that uses heart sound…